Accordingly, LYVE-1+ dural macrophages are likely the primary targets of CLL treatment, given their close association with MLVs in the dural sinuses, and their better phagocytic capability than that of LYVE-1– macrophages, as previously reported.17 Here, LYVE1 is linked to B-cell chronic lymphocytic leukemia.